Lifecore Biomedical, Inc. \de\ LFCR
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Lifecore Biomedical, Inc. \de\ (LFCR) is a healthcare company listed in the US with a market value of about $243M. In fiscal year 2025 it had revenue of $129M and net income of -$39M, a net margin of -30.0%.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -8%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 66% below the current price.
About Lifecore Biomedical, Inc. \de\
Lifecore Biomedical, Inc. \de\ is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $101M in 2021 to $129M in 2025, growth of about 6.3% a year. It was profitable in 1 of the last 5 years in our data. Its share count rose by 18% over three years (dilution for shareholders). It spends 6% of revenue on research and development.
Score: 0.4 / 5
Checks passed
- Profit margin improving
- Strong R&D investment or growth above 20%
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 5 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $129M | $128M | $103M | $111M | $101M |
| Net income | -$39M | $12M | -$100M | -$117M | -$32M |
| Free cash flow | -$14M | -$18M | — | -$49M | -$3M |
| EPS (diluted) | $-1.27 | $0.33 | $-3.32 | $-3.97 | $-1.10 |
| Net margin | -30.0% | 9.4% | -96.4% | -104.9% | -32.0% |
| ROIC | -10.2% | -6.1% | -19.5% | -4.5% | -1.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $6.28, 2% below the current price; targets range from $6.28 to $6.28; the consensus rating is “Hold”; expected EPS is $-1.83 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Lifecore Biomedical, Inc. \de\ stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 66% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Lifecore Biomedical, Inc. \de\ pay a dividend?
Not currently.
Is Lifecore Biomedical, Inc. \de\ a good stock to buy?
We do not give buy or sell advice. Lifecore Biomedical, Inc. \de\ scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.